Don’t miss Orioles players, John Means & Paul Fry, as they guest host at our Brews and O’s event!

Rockville biotech MaxCyte to work with Hopkins on cancer immunotherapy research

A Rockville biotech company is tapping expertise at Johns Hopkins to pursue a new cancer immunotherapy.

Rockville biotechnology company MaxCyte Inc. announced Tuesday it is collaborating with Johns Hopkins University researchers to explore a way to use the immune system to fight cancer.

The scientists are developing a therapy tool known as Chimeric Antigen Receptor T-cells, which target tumors. Immunotherapy is a fast-growing area of cancer research.

MaxCyte CEO Doug Doerfler said the collaboration will help push the research toward clinical testing. Company officials said they expect the research at Hopkins to support an application for Food and Drug Administration approval of the therapy.

The company would not disclose financial terms of the partnership.

Copyright © 2019, The Baltimore Sun, a Baltimore Sun Media Group publication | Place an Ad